for subcutaneous or intravenous use Initial U.S. Approval: 2009
ustekinumab injection is a human interleukin-12 and -23 antagonist indicated for the treatment of adult patients with: • moderate to severe plaque psoriasis (Ps) who are candidates for phototherapy or systemic therapy. • active psoriatic arthritis (PsA), alone or in combination with methotrexate. • moderately to severely active Crohn’s disease (CD).
Facts about ustekinumab injection
DISEASE INDICATIONS-Plaque Psoriasis, psoriatic arthritis, Crohn’s disease, or ulcerative colitis.
MEDICINE APPROVED BY-The European Medicines Agency (EMA), Food and Drug Administration (FDA)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “ustekinumab injection” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For ustekinumab injection
Approved accessible "ustekinumab injection"
Ustekinumab, sold under the brand name Stelara is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis,targeting both IL-12 and IL-23.
Ustekinumab is approved to treat Crohn's disease in the United States, Israel, Australia, and the European Union (EU), and ulcerative colitis in the US, and in the EU to patients who have not responded to more traditional treatments. It was found not effective for multiple sclerosis.
How can 1 go about obtaining ustekinumab injection?
If ustekinumab injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
STELARA (ustekinumab) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2009
- Full prescribing information [EMA]: Stelara (ustekinumab) [PDF] Janssen, Jan 2009
- Stelara (ustekinumab) product page EMA, Jan 15, 2009
- Stelara-H-C-958-II-0073 : EPAR - Assessment Report - Variation [PDF] EMA, Jan 15, 2020
- STELARA® (Ustekinumab) Receives FDA Approval To Treat Active Psoriatic Arthritis Janssen press release, Sept 23, 2013
- FDA Approves Stelara (ustekinumab) for Treatment of Adults with Moderately to Severely Active Crohn's Disease Press release Sept 26, 2016
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa